Dark Forest Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Dark Forest Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,330	Closed	-$62.5K	–	1199
2023 Q2	$62.5K	Buy	+2,330	New	+$100K	0.01%	983
2022 Q4	–	Sell	-51	Closed	-$4K	–	1327
2022 Q3	$4K	Buy	+51	New	+$3.81K	﹤0.01%	936
2022 Q1	–	Sell	-1	Closed	–	–	1543
2021 Q4	$0	Sell	1 -27	-96%	-$2.69K	﹤0.01%	1615
2021 Q3	$2K	Buy	+28	New	+$2.91K	﹤0.01%	1167

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dark Forest Capital Management's KPTI Position: Q3 2023 in Review

Dark Forest Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 2,330 shares — an estimated $62.5K sold.

Dark Forest Capital Management first reported a position in KPTI in Q3 2021 and held it in 4 quarters. The position peaked at $62.5K in Q2 2023. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

Dark Forest Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
Dark Forest Capital Management sold 2,330 Karyopharm Therapeutics shares in Q3 2023, an estimated $62.5K.
Dark Forest Capital Management first reported a position in Karyopharm Therapeutics in Q3 2021 and held it in 4 quarters.
Dark Forest Capital Management's Karyopharm Therapeutics position peaked at $62.5K in Q2 2023.
118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Dark Forest Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.